{"count":839,"next":"http://glycodata.org/api/gdd/glyco-properties/?format=json&page=35","previous":"http://glycodata.org/api/gdd/glyco-properties/?format=json&page=33","results":[{"id":661,"dataset":"heparin","entity":"heparin decasaccharide (dp10, canonical)","entity_group":"","entity_class":"heparin oligosaccharide","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"1.3","unit":"µM","value_reported":"1.3","unit_reported":"µM","method":"Experiment","method_detail":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 10b)","conditions":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 10b)","conditions_detail":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 10b) | partner: VEGF165 | technique: SPR","doi":"10.1042/BSR20110077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3190640/","year":"2012","confidence":"high","comments":"\"10b (decasaccharide) ... VEGF165 1.3 ± 0.3 µM (SPR solution affinity)\"  — Decasaccharide vs VEGF165; Table 2  [Zhao W, McCallum SA, Xiao Z, Zhang F, Linhardt RJ, 2012, confidence: high]"},{"id":662,"dataset":"heparin","entity":"heparin tetradecasaccharide (dp14)","entity_group":"","entity_class":"heparin oligosaccharide","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.09","unit":"µM","value_reported":"90","unit_reported":"nM","method":"Experiment","method_detail":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 14b)","conditions":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 14b)","conditions_detail":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 14b) | partner: VEGF165 | technique: SPR","doi":"10.1042/BSR20110077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3190640/","year":"2012","confidence":"high","comments":"\"14b (tetradecasaccharide) ... VEGF165 90 ± 5 nM; a tetradecasaccharide displayed an effective binding affinity to VEGF165 comparable to unfractionated heparin\"  — dp14 binds VEGF165 comparably to UFH; Table 2  [Zhao W, McCallum SA, Xiao Z, Zhang F, Linhardt RJ, 2012, confidence: high]"},{"id":663,"dataset":"heparin","entity":"heparin hexadecasaccharide (dp16)","entity_group":"","entity_class":"heparin oligosaccharide","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.113","unit":"µM","value_reported":"113","unit_reported":"nM","method":"Experiment","method_detail":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 16b)","conditions":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 16b)","conditions_detail":"Kd vs VEGF165 by SPR solution affinity assay (oligosaccharide 16b) | partner: VEGF165 | technique: SPR","doi":"10.1042/BSR20110077","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3190640/","year":"2012","confidence":"high","comments":"\"16b (hexadecasaccharide) ... VEGF165 113 ± 26 nM (SPR solution affinity)\"  — dp16 vs VEGF165; Table 2  [Zhao W, McCallum SA, Xiao Z, Zhang F, Linhardt RJ, 2012, confidence: high]"},{"id":664,"dataset":"heparin","entity":"heparan sulfate (sulfated domains)","entity_group":"","entity_class":"heparan sulfate","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.03","unit":"µM","value_reported":"30","unit_reported":"nM","method":"Experiment","method_detail":"Kd of SDF-1/CXCL12 binding to the sulfated regions of heparan sulfate","conditions":"Kd of SDF-1/CXCL12 binding to the sulfated regions of heparan sulfate","conditions_detail":"Kd of SDF-1/CXCL12 binding to the sulfated regions of heparan sulfate | partner: SDF-1 / CXCL12 (stromal cell-derived factor-1) | technique: binding assay","doi":"10.1074/jbc.M311439200","source_url":"https://www.sciencedirect.com/science/article/pii/S0021925820680589","year":"2004","confidence":"medium","comments":"\"SDF-1 binds with high affinity (Kd of 30 nM) to the sulfated regions of heparan sulfate (HS)\"  — SDF-1/CXCL12-HS Kd; value from web search summary of this SDF-1/HS paper  [Sadir R, Imberty A, Baleux F, Lortat-Jacob H, 2004, confidence: medium]"},{"id":665,"dataset":"heparin","entity":"heparin octasaccharide (dp8)","entity_group":"","entity_class":"heparin oligosaccharide","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"34","unit":"µM","value_reported":"34","unit_reported":"µM","method":"Experiment","method_detail":"Apparent Kd for 1:1 complex of heparin octasaccharide with disulfide-trapped CXCL1 dimer, by solution NMR chemical-shift-perturbation titration","conditions":"Apparent Kd for 1:1 complex of heparin octasaccharide with disulfide-trapped CXCL1 dimer, by solution NMR chemical-shift-perturbation titration","conditions_detail":"Apparent Kd for 1:1 complex of heparin octasaccharide with disulfide-trapped CXCL1 dimer, by solution NMR chemical-shift-perturbation titration | partner: CXCL1 (chemokine) dimer | technique: NMR","doi":"10.1074/jbc.M113.492579","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3757178/","year":"2013","confidence":"high","comments":"\"The calculated apparent dissociation constant for a 1:1 complex is 34 ± 6 µm\"  — Heparin octasaccharide vs CXCL1 dimer (dCXCL1); NMR titration  [Poluri KM, Joseph PRB, Sawant KV, Rajarathnam K, 2013, confidence: high]"},{"id":666,"dataset":"heparin","entity":"heparin","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.055","unit":"µM","value_reported":"55","unit_reported":"nM","method":"Experiment","method_detail":"KD of full-length monomeric SARS-CoV-2 spike protein binding to immobilized heparin by SPR","conditions":"KD of full-length monomeric SARS-CoV-2 spike protein binding to immobilized heparin by SPR","conditions_detail":"KD of full-length monomeric SARS-CoV-2 spike protein binding to immobilized heparin by SPR | partner: SARS-CoV-2 spike protein (full-length monomeric) | technique: SPR","doi":"10.1021/acscentsci.1c00010","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8227597/","year":"2021","confidence":"high","comments":"\"The full-length monomeric spike protein showed a much higher binding affinity with a KD value of 55 nM\"  — SARS-CoV-2 spike (monomeric) vs heparin; SPR  [Liu L, Chopra P, Li X, Bouwman KM, Tompkins SM, et al., 2021, confidence: high]"},{"id":667,"dataset":"heparin","entity":"heparin","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.064","unit":"µM","value_reported":"64","unit_reported":"nM","method":"Experiment","method_detail":"KD of trimeric SARS-CoV-2 spike protein binding to immobilized heparin by SPR","conditions":"KD of trimeric SARS-CoV-2 spike protein binding to immobilized heparin by SPR","conditions_detail":"KD of trimeric SARS-CoV-2 spike protein binding to immobilized heparin by SPR | partner: SARS-CoV-2 spike protein (trimeric) | technique: SPR","doi":"10.1021/acscentsci.1c00010","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8227597/","year":"2021","confidence":"high","comments":"\"The trimeric spike protein displayed a similar binding affinity (KD = 64 nM)\"  — SARS-CoV-2 spike (trimeric) vs heparin; SPR  [Liu L, Chopra P, Li X, Bouwman KM, Tompkins SM, et al., 2021, confidence: high]"},{"id":668,"dataset":"heparin","entity":"heparin","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"1","unit":"µM","value_reported":"1","unit_reported":"µM","method":"Experiment","method_detail":"KD of SARS-CoV-2 receptor binding domain (RBD) binding to immobilized heparin by SPR","conditions":"KD of SARS-CoV-2 receptor binding domain (RBD) binding to immobilized heparin by SPR","conditions_detail":"KD of SARS-CoV-2 receptor binding domain (RBD) binding to immobilized heparin by SPR | partner: SARS-CoV-2 spike receptor binding domain (RBD) | technique: SPR","doi":"10.1021/acscentsci.1c00010","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8227597/","year":"2021","confidence":"high","comments":"\"The RBD domain binds to heparin with a moderate affinity having a KD value of ~1 µM\"  — SARS-CoV-2 spike RBD vs heparin; SPR  [Liu L, Chopra P, Li X, Bouwman KM, Tompkins SM, et al., 2021, confidence: high]"},{"id":669,"dataset":"heparin","entity":"heparin (end-chain immobilized)","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.021","unit":"µM","value_reported":"21","unit_reported":"nM","method":"Experiment","method_detail":"Kd of annexin V binding to end-chain immobilized heparin by SPR","conditions":"Kd of annexin V binding to end-chain immobilized heparin by SPR","conditions_detail":"Kd of annexin V binding to end-chain immobilized heparin by SPR | partner: annexin V | technique: SPR","doi":"10.1016/S0014-5793(99)00245-8","source_url":"https://www.sciencedirect.com/science/article/pii/S0014579399002458","year":"1999","confidence":"medium","comments":"\"Surface plasmon resonance analysis afforded a Kd of approximately 21 nM for the interaction of annexin V with end-chain immobilized heparin\"  — Annexin V vs heparin; value via web search summary (full text 403)  [Capila I, VanderNoot VA, Mealy TR, Seaton BA, Linhardt RJ, 1999, confidence: medium]"},{"id":670,"dataset":"heparin","entity":"heparan sulfate (end-chain immobilized)","entity_group":"","entity_class":"heparan sulfate","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.049","unit":"µM","value_reported":"49","unit_reported":"nM","method":"Experiment","method_detail":"Kd of annexin V binding to end-chain immobilized heparan sulfate by SPR","conditions":"Kd of annexin V binding to end-chain immobilized heparan sulfate by SPR","conditions_detail":"Kd of annexin V binding to end-chain immobilized heparan sulfate by SPR | partner: annexin V | technique: SPR","doi":"10.1016/S0014-5793(99)00245-8","source_url":"https://www.sciencedirect.com/science/article/pii/S0014579399002458","year":"1999","confidence":"medium","comments":"\"a Kd of approximately 49 nM for the interaction with end-chain immobilized heparan sulfate\"  — Annexin V vs heparan sulfate; value via web search summary (full text 403)  [Capila I, VanderNoot VA, Mealy TR, Seaton BA, Linhardt RJ, 1999, confidence: medium]"},{"id":671,"dataset":"heparin","entity":"heparin","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.032","unit":"µM","value_reported":"32","unit_reported":"nM","method":"Experiment","method_detail":"Apparent Kd of annexin II tetramer binding to heparin, stoichiometry 11 mol tetramer per mol heparin","conditions":"Apparent Kd of annexin II tetramer binding to heparin, stoichiometry 11 mol tetramer per mol heparin","conditions_detail":"Apparent Kd of annexin II tetramer binding to heparin, stoichiometry 11 mol tetramer per mol heparin | partner: annexin II tetramer | technique: binding assay","doi":"10.1074/jbc.272.24.15093","source_url":"https://www.sciencedirect.com/science/article/pii/S002192581839450X","year":"1997","confidence":"medium","comments":"\"Annexin II tetramer bound to heparin with an apparent Kd of 32 ± 6 nM with a stoichiometry of 11 ± 0.9 mol of annexin II tetramer per mol of heparin\"  — Annexin II tetramer vs heparin; value via web search summary (full text 403)  [Kassam G, Manro A, Braat CE, Louie P, Fitzpatrick SL, Waisman DM, 1997, confidence: medium]"},{"id":672,"dataset":"heparin","entity":"heparin","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.0031","unit":"µM","value_reported":"3.1","unit_reported":"nM","method":"Experiment","method_detail":"Kd of heparin binding to RAGE (receptor for advanced glycation endproducts)","conditions":"Kd of heparin binding to RAGE (receptor for advanced glycation endproducts)","conditions_detail":"Kd of heparin binding to RAGE (receptor for advanced glycation endproducts) | partner: RAGE (receptor for advanced glycation endproducts) | technique: binding assay","doi":"10.1021/acs.jmedchem.7b00058","source_url":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00058","year":"2022","confidence":"medium","comments":"\"chondroitin sulfate E, heparan sulfate, and heparin have high affinity for RAGE with Kd values of 0.2, 0.6, and 3.1 nM, respectively\"  — Heparin vs RAGE; value via web search summary  [Singh H, Agrawal DK, 2022, confidence: medium]"},{"id":673,"dataset":"heparin","entity":"heparan sulfate","entity_group":"","entity_class":"heparan sulfate","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"0.0006","unit":"µM","value_reported":"0.6","unit_reported":"nM","method":"Experiment","method_detail":"Kd of heparan sulfate binding to RAGE","conditions":"Kd of heparan sulfate binding to RAGE","conditions_detail":"Kd of heparan sulfate binding to RAGE | partner: RAGE (receptor for advanced glycation endproducts) | technique: binding assay","doi":"10.1021/acs.jmedchem.7b00058","source_url":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00058","year":"2022","confidence":"medium","comments":"\"chondroitin sulfate E, heparan sulfate, and heparin have high affinity for RAGE with Kd values of 0.2, 0.6, and 3.1 nM, respectively\"  — Heparan sulfate vs RAGE; value via web search summary  [Singh H, Agrawal DK, 2022, confidence: medium]"},{"id":674,"dataset":"heparin","entity":"heparin (low-affinity, full-length)","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"6","unit":"µM","value_reported":"6","unit_reported":"µM","method":"Experiment","method_detail":"Intrinsic dissociation constant (KD,obs ~ 6-10 microM) of thrombin-heparin interaction at physiological ionic strength","conditions":"Intrinsic dissociation constant (KD,obs ~ 6-10 microM) of thrombin-heparin interaction at physiological ionic strength","conditions_detail":"Intrinsic dissociation constant (KD,obs ~ 6-10 microM) of thrombin-heparin interaction at physiological ionic strength | partner: thrombin | technique: fluorescence/SPR (bulk)","doi":"10.1016/j.abb.2008.03.044","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3461310/","year":"2008","confidence":"medium","comments":"\"The thrombin-heparin interaction was characterized by an intrinsic dissociation constant (KD,obs) of 6-10 microM at physiological ionic strength\"  — Thrombin-heparin (exosite II) low-affinity binding; value via web search summary; range 6-10 uM (lower bound recorded)  [Verhamme IM, Bock PE, 2008, confidence: medium]"},{"id":675,"dataset":"heparin","entity":"heparin","entity_group":"","entity_class":"heparin (UFH)","property":"protein binding affinity (Kd)","property_key":"binding_affinity","value":"20","unit":"µM","value_reported":"20","unit_reported":"µM","method":"Experiment","method_detail":"Equilibrium dissociation constant K_HCII(Hep) for heparin binding to heparin cofactor II","conditions":"Equilibrium dissociation constant K_HCII(Hep) for heparin binding to heparin cofactor II","conditions_detail":"Equilibrium dissociation constant K_HCII(Hep) for heparin binding to heparin cofactor II | partner: heparin cofactor II (HCII) | technique: fluorescence","doi":"10.1016/j.abb.2008.03.044","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3461310/","year":"2008","confidence":"medium","comments":"\"KHCII(Hep) = 20 ± 5 µM, similar to the values reported independently by us and others\"  — Heparin cofactor II vs heparin; value via web search summary  [Verhamme IM, Bock PE, 2008, confidence: medium]"},{"id":676,"dataset":"heparin","entity":"heparin (porcine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"72.6","unit":"%","value_reported":"72.6","unit_reported":"%","method":"Experiment","method_detail":"mol% of TriS disaccharide (UA2S-GlcNS6S) in unfractionated heparin (UFH), LC-MS disaccharide analysis after heparin lyase digestion","conditions":"mol% of TriS disaccharide (UA2S-GlcNS6S) in unfractionated heparin (UFH), LC-MS disaccharide analysis after heparin lyase digestion","conditions_detail":"mol% of TriS disaccharide (UA2S-GlcNS6S) in unfractionated heparin (UFH), LC-MS disaccharide analysis after heparin lyase digestion | unit id: TriS (UA2S-GlcNS6S) | source: porcine intestinal","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"TriS...72.6 ± 0.3\"  — UFH starting material; dominant trisulfated unit  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"},{"id":677,"dataset":"heparin","entity":"heparin (porcine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"14.1","unit":"%","value_reported":"14.1","unit_reported":"%","method":"Experiment","method_detail":"mol% of NS6S disaccharide (UA-GlcNS6S) in UFH, LC-MS disaccharide analysis","conditions":"mol% of NS6S disaccharide (UA-GlcNS6S) in UFH, LC-MS disaccharide analysis","conditions_detail":"mol% of NS6S disaccharide (UA-GlcNS6S) in UFH, LC-MS disaccharide analysis | unit id: NS6S (UA-GlcNS6S) | source: porcine intestinal","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"ΔDi-NS6S...14.1 ± 0.8\"  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"},{"id":678,"dataset":"heparin","entity":"heparin (porcine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"5.4","unit":"%","value_reported":"5.4","unit_reported":"%","method":"Experiment","method_detail":"mol% of NS2S disaccharide (UA2S-GlcNS) in UFH, LC-MS disaccharide analysis","conditions":"mol% of NS2S disaccharide (UA2S-GlcNS) in UFH, LC-MS disaccharide analysis","conditions_detail":"mol% of NS2S disaccharide (UA2S-GlcNS) in UFH, LC-MS disaccharide analysis | unit id: NS2S (UA2S-GlcNS) | source: porcine intestinal","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"ΔDi-NS2S...5.4 ± 0.2\"  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"},{"id":679,"dataset":"heparin","entity":"heparin (porcine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"1.9","unit":"%","value_reported":"1.9","unit_reported":"%","method":"Experiment","method_detail":"mol% of NS disaccharide (UA-GlcNS) in UFH, LC-MS disaccharide analysis","conditions":"mol% of NS disaccharide (UA-GlcNS) in UFH, LC-MS disaccharide analysis","conditions_detail":"mol% of NS disaccharide (UA-GlcNS) in UFH, LC-MS disaccharide analysis | unit id: NS (UA-GlcNS) | source: porcine intestinal","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"ΔDi-NS...1.9 ± 0.1\"  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"},{"id":680,"dataset":"heparin","entity":"heparin (porcine intestinal)","entity_group":"","entity_class":"heparin (UFH)","property":"disaccharide composition","property_key":"disaccharide_composition","value":"0.8","unit":"%","value_reported":"0.8","unit_reported":"%","method":"Experiment","method_detail":"mol% of unsulfated 0S disaccharide (UA-GlcNAc) in UFH, LC-MS disaccharide analysis","conditions":"mol% of unsulfated 0S disaccharide (UA-GlcNAc) in UFH, LC-MS disaccharide analysis","conditions_detail":"mol% of unsulfated 0S disaccharide (UA-GlcNAc) in UFH, LC-MS disaccharide analysis | unit id: 0S / unsulfated (UA-GlcNAc) | source: porcine intestinal","doi":"10.1002/jps.23939","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/","year":"2014","confidence":"high","comments":"\"ΔDi-0S...0.8 ± 0.2\"  — very low unsulfated content is characteristic of heparin vs HS  [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]"}]}